Clinical trial NCT03493451 - References

Anaplastic Large Cell Lymphoma — Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Citation(s)

•   Huiqiang Huang, et al
  Tislelizumab (BGB-A317) for relapsed/refractory extranodal NK/T-cell lymphoma: preliminary efficacy and safety results from a phase 2 study. Poster Abstract EP1268, European Hematology Association 2020.
•   Pier Luigi Zinzani, et al
  Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: Safety and efficacy results from a phase 2 study. Poster Abstract EP1235, European Hematology Association 2020.

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Details for clinical trial NCT03493451